CAR T-CELL THERAP FIRST-IN-HUMAN TRIAL FOR N
In 2024, a first-in-human trial of CAR T-cell therapy in NETs will begin, made University of Pennsylvania, USA.
WHY CAR T-CELL THERAPY MATTERS: CAR T-cell therapy, or Chimeric Antigen Receptor T-cell Therapy, represents own immune cells to target and destroy cancer cells. Dr. Hua's leadership in the boundaries of NET research. Here is an exert from the Neuroendocrine Tumor Research Foundation an The Neuroendocrine Tumor Research Foundation celebrates a significant mi tumors (NETs) will open in 2024. NETRF supported the early-stage, preclinic Chimeric Therapeutics, an Australian leader in cell therapy, built upon the pre 2101. In October, Chimeric announced that the FDA approved CHM 2101 for the safety and efficacy of the therapy. CHM 2101 is poised to be the first CDH “NETRF is proud to have supported Dr. Hua’s research, which has led to this NETRF’s impact on the NET research landscape by supporting early high-ris research helped to ensure that there was a team focused on applying CAR T overlooked. NETRF’s involvement with this research began in 2014. Lauren Erb, former N Hua, MD, PhD, and David Metz, MD at the University of Pennsylvania to urg followed by a 2018 Petersen Accelerator Award to Dr. Hua. “Congratulations 1 trial, says Erb. “This is a true testament to the impact NETRF can have on patients and in less than ten years they have done that.” Over the years, significant progress has been made in cancer immunotherap promising immunotherapy avenue is the use of CAR T cells, which are T cell cancers, their use in solid tumors has been hampered for several reasons inc without harming the patient’s normal cells...
CLICK HERE TO READ THE FULL ARTICLE
Made with FlippingBook flipbook maker